Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20000832 | 0.84 | GRIN2D (0.31) | — | |
| SCHEMBL14868284 | 0.78 | — | — | |
| SCHEMBL16492054 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7782684 | 0.77 | F2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL1937317 | 0.76 | GRIN2D (0.32) | — | |
| SCHEMBL23685217 | 0.75 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL14868274 | 0.74 | SPHK2 (0.34) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL7772449 | 0.74 | NOS3 (0.33) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL23685215 | 0.74 | — | — | |
| SCHEMBL16489818 | 0.73 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344002-B2 | Compositions and methods for treating metabolic disorders | NUSIRT SCIENCES, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| WO-2018058109-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344002-B2 | Compositions and methods for treating metabolic disorders | LIPC, PC, PNLIP | NOS3 1016/4885NOS1 1173/4885NOS2 1017/4885 |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | LIPC, PC, PNLIP | NOS3 1016/4885NOS1 1173/4885NOS2 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.